CYBERDYNE Inc. (JP:7779)
:7779
Want to see JP:7779 full AI Analyst Report?
Top Page
CYBERDYNE
(7779)
Select Model
Select Model
Rating:56Neutral
Price Target:
¥301.00
▲(39.35% Upside)
Action:ReiteratedDate:02/18/26
The score is held back primarily by weak financial performance—ongoing net losses and persistent negative operating/free cash flow—despite a very strong, low-leverage balance sheet. Technicals are a major positive, showing a clear uptrend and strong momentum. Valuation remains unattractive because earnings are negative (negative P/E) and there is no dividend yield data to offset that.
Positive Factors
Strong balance sheet
Very low leverage and a stable equity base provide long-term financial flexibility: management can fund R&D, clinical deployments, and partnerships without urgent refinancing. This cushioning supports multi‑month to multi‑year commercialization and regulatory timelines in medical robotics.
Negative Factors
Persistent net losses and weak cash generation
Ongoing losses and negative operating/free cash flow mean the business does not self‑fund its growth. Over a durable horizon, sustained cash burn risks depleting reserves or forcing dilutive funding, limiting ability to scale clinical deployments without external capital or margin improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Very low leverage and a stable equity base provide long-term financial flexibility: management can fund R&D, clinical deployments, and partnerships without urgent refinancing. This cushioning supports multi‑month to multi‑year commercialization and regulatory timelines in medical robotics.
Read all positive factors
CYBERDYNE (7779) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥61.65B
Dividend YieldN/A
Average Volume (3M)724.97K
Price to Earnings (P/E)87.8
Beta (1Y)0.84
Revenue Growth-4.55%
EPS Growth99.67%
CountryJP
Employees227
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.01
Shares Outstanding137,445,820
10 Day Avg. Volume764,380
30 Day Avg. Volume724,970
Financial Highlights & Ratios
PEG Ratio1.05
Price to Book (P/B)0.93
Price to Sales (P/S)8.43
P/FCF Ratio-50.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥410.00Price Target Upside89.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.03
Revenue Forecast (FY)¥4.96B
CYBERDYNE Business Overview & Revenue Model
Company Description
CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains equipment and systems for medical and warfare in Japan. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL ...
How the Company Makes Money
CYBERDYNE generates revenue primarily by providing its HAL wearable exoskeleton systems and related services to customers in healthcare, rehabilitation, and care environments. Key revenue streams include (1) the sale and/or provision of HAL units ...
CYBERDYNE Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
78
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.11B | 4.38B | 4.35B | 3.29B | 2.15B | 1.88B |
| Gross Profit | 2.05B | 2.07B | 2.03B | 1.49B | 1.25B | 1.11B |
| EBITDA | -505.00M | -904.00M | -1.06B | -722.00M | -565.00M | -413.00M |
| Net Income | -3.00M | -577.00M | -1.48B | -298.00M | -498.00M | -59.00M |
Balance Sheet | ||||||
| Total Assets | 49.00B | 48.55B | 50.00B | 50.19B | 49.47B | 48.12B |
| Cash, Cash Equivalents and Short-Term Investments | 9.20B | 6.82B | 5.16B | 7.80B | 20.83B | 6.70B |
| Total Debt | 434.00M | 434.00M | 632.00M | 669.00M | 575.00M | 421.00M |
| Total Liabilities | 9.21B | 8.95B | 9.52B | 8.20B | 6.02B | 4.33B |
| Stockholders Equity | 39.80B | 39.58B | 40.75B | 42.10B | 43.41B | 43.78B |
Cash Flow | ||||||
| Free Cash Flow | -222.00M | -726.00M | -1.07B | -594.00M | -2.33B | -1.84B |
| Operating Cash Flow | -177.00M | -430.00M | -850.00M | -143.00M | -564.00M | -775.00M |
| Investing Cash Flow | 5.56B | 2.33B | -2.08B | 2.17B | -1.79B | -2.79B |
| Financing Cash Flow | -226.00M | -216.00M | 160.00M | 14.00M | 1.25B | 617.00M |
CYBERDYNE Technical Analysis
Positive
216.00
Price Trends
310.64
Negative
258.69
Positive
222.66
Positive
Market Momentum
-5.76
Negative
52.80
Neutral
78.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7779, the sentiment is Positive. The current price of 216 is below the 20-day moving average (MA) of 282.45, below the 50-day MA of 310.64, and below the 200-day MA of 222.66, indicating a neutral trend. The MACD of -5.76 indicates Negative momentum. The RSI at 52.80 is Neutral, neither overbought nor oversold. The STOCH value of 78.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7779.
CYBERDYNE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥10.87B | 44.27 | ― | 3.52% | 4.51% | -11.56% | |
67 Neutral | ¥8.85B | 4.38 | ― | 1.89% | 10.17% | 23.10% | |
65 Neutral | ¥240.81B | 36.37 | ― | 1.92% | 2.97% | -26.69% | |
64 Neutral | ¥13.75B | 14.76 | ― | 3.12% | -0.24% | -174.33% | |
56 Neutral | ¥61.65B | 87.82 | -0.46% | ― | -4.55% | 99.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥127.36B | 28.05 | 2.42% | 3.73% | -0.05% | -40.08% |
* Healthcare Sector Average
JP:7779
CYBERDYNE
292.00
118.00
67.82%
JP:6523
PHC Holdings Corp.
1,005.00
76.64
8.26%
JP:5187
Create Medic Co., Ltd.
1,195.00
270.82
29.30%
JP:6849
Nihon Kohden Corporation
1,442.50
-251.87
-14.86%
JP:7600
Japan Medical Dynamic Marketing, Inc.
522.00
-12.82
-2.40%
JP:7963
Koken Ltd.
1,800.00
239.89
15.38%
CYBERDYNE Corporate Events
CYBERDYNE Extends SIP Smart Mobility R&D Contract and Increases Project Funding
Mar 26, 2026
CYBERDYNE Inc. has amended its business consignment agreement under Japan’s Cross-ministerial Strategic Innovation Promotion Program, Third Phase, for the development of a smart mobility platform. The project targets Theme 12, which focuses ...
CYBERDYNE Extends SIP Robotics Contract and Lifts Consignment Budget
Mar 18, 2026
CYBERDYNE Inc. has amended its business consignment agreement under Japan’s Cross-ministerial Strategic Innovation Promotion Program, which supports the development and social implementation of integrated human-collaborative robotics in Huma...
Cyberdyne Narrows Losses and Returns to Profit Despite Revenue Decline
Feb 12, 2026
CYBERDYNE reported consolidated revenue of ¥2.89 billion for the nine months ended December 31, 2025, down 8.7% year-on-year, but significantly improved profitability, moving from an operating loss of ¥708 million to a smaller loss of &#...
CYBERDYNE Increases SIP Consignment Budget Under NEDO Robotics Project
Feb 5, 2026
CYBERDYNE Inc. has amended its business consignment agreement with Japan’s New Energy and Industrial Technology Development Organization (NEDO) under the government-led Strategic Innovation Promotion Program (SIP) focused on human collaborat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.